OTCMKTS:INNVD

Innovus Pharmaceuticals Competitors

$3.00
+1.77 (+143.90 %)
(As of 04/11/2019)
Add
Compare
Today's Range
$2.65
Now: $3.00
$3.49
50-Day Range
$1.23
MA: $2.68
$3.00
52-Week Range
$1.50
Now: $3.00
$19.37
Volume4,300 shs
Average Volume9,592 shs
Market Capitalization$7.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.89

Competitors

Innovus Pharmaceuticals (OTCMKTS:INNVD) Vs. NXEN, TOWTF, TRLPF, PKPH, GBIM, and WHCA

Should you be buying INNVD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Innovus Pharmaceuticals, including Nexien BioPharma (NXEN), Tower One Wireless (TOWTF), Acerus Pharmaceuticals (TRLPF), Peak Pharmaceuticals (PKPH), GlobeImmune (GBIM), and Williston (WHCA).

Nexien BioPharma (OTCMKTS:NXEN) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Earnings & Valuation

This table compares Nexien BioPharma and Innovus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexien BioPharmaN/AN/A$-2,670,000.00N/AN/A
Innovus Pharmaceuticals$23.99 million0.29$-8,280,000.00($4.16)-0.72

Nexien BioPharma has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Risk and Volatility

Nexien BioPharma has a beta of -701.47, meaning that its stock price is 70,247% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 30.6% of Nexien BioPharma shares are owned by company insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Nexien BioPharma and Innovus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nexien BioPharma0000N/A
Innovus Pharmaceuticals0000N/A

Profitability

This table compares Nexien BioPharma and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nexien BioPharmaN/A-16,049.80%-6,651.95%
Innovus Pharmaceuticals-34.51%-682.54%-78.57%

Summary

Innovus Pharmaceuticals beats Nexien BioPharma on 5 of the 8 factors compared between the two stocks.

Tower One Wireless (OTCMKTS:TOWTF) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Tower One Wireless has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500.

Valuation & Earnings

This table compares Tower One Wireless and Innovus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tower One Wireless$4.08 million2.73$-3,750,000.00N/AN/A
Innovus Pharmaceuticals$23.99 million0.29$-8,280,000.00($4.16)-0.72

Tower One Wireless has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Tower One Wireless and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tower One WirelessN/AN/A-39.36%
Innovus Pharmaceuticals-34.51%-682.54%-78.57%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tower One Wireless and Innovus Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tower One Wireless0000N/A
Innovus Pharmaceuticals0000N/A

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Volatility & Risk

Acerus Pharmaceuticals has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, suggesting that its stock price is 189% more volatile than the S&P 500.

Earnings and Valuation

This table compares Acerus Pharmaceuticals and Innovus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acerus Pharmaceuticals$7.38 million4.05$-18,790,000.00N/AN/A
Innovus Pharmaceuticals$23.99 million0.29$-8,280,000.00($4.16)-0.72

Innovus Pharmaceuticals has higher revenue and earnings than Acerus Pharmaceuticals.

Profitability

This table compares Acerus Pharmaceuticals and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acerus Pharmaceuticals-254.66%-346.72%-94.54%
Innovus Pharmaceuticals-34.51%-682.54%-78.57%

Institutional & Insider Ownership

0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Comparatively, 10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Acerus Pharmaceuticals and Innovus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acerus Pharmaceuticals0000N/A
Innovus Pharmaceuticals0000N/A

Summary

Innovus Pharmaceuticals beats Acerus Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Risk and Volatility

Innovus Pharmaceuticals has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Innovus Pharmaceuticals and Peak Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innovus Pharmaceuticals0000N/A
Peak Pharmaceuticals0000N/A

Earnings & Valuation

This table compares Innovus Pharmaceuticals and Peak Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovus Pharmaceuticals$23.99 million0.29$-8,280,000.00($4.16)-0.72
Peak PharmaceuticalsN/AN/AN/AN/AN/A

Peak Pharmaceuticals has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Profitability

This table compares Innovus Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innovus Pharmaceuticals-34.51%-682.54%-78.57%
Peak PharmaceuticalsN/AN/AN/A

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Innovus Pharmaceuticals beats Peak Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and GlobeImmune (OTCMKTS:GBIM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Risk and Volatility

Innovus Pharmaceuticals has a beta of 2.89, suggesting that its share price is 189% more volatile than the S&P 500. Comparatively, GlobeImmune has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Innovus Pharmaceuticals and GlobeImmune, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innovus Pharmaceuticals0000N/A
GlobeImmune0000N/A

Earnings & Valuation

This table compares Innovus Pharmaceuticals and GlobeImmune's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovus Pharmaceuticals$23.99 million0.29$-8,280,000.00($4.16)-0.72
GlobeImmuneN/AN/AN/AN/AN/A

GlobeImmune has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Profitability

This table compares Innovus Pharmaceuticals and GlobeImmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innovus Pharmaceuticals-34.51%-682.54%-78.57%
GlobeImmuneN/AN/AN/A

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by company insiders. Comparatively, 23.5% of GlobeImmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

GlobeImmune beats Innovus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Williston (OTCMKTS:WHCA) and Innovus Pharmaceuticals (OTCMKTS:INNVD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Williston and Innovus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Williston0000N/A
Innovus Pharmaceuticals0000N/A

Volatility & Risk

Williston has a beta of -1.09, meaning that its share price is 209% less volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Williston and Innovus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WillistonN/AN/AN/A
Innovus Pharmaceuticals-34.51%-682.54%-78.57%

Earnings and Valuation

This table compares Williston and Innovus Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WillistonN/AN/AN/AN/AN/A
Innovus Pharmaceuticals$23.99 million0.29$-8,280,000.00($4.16)-0.72

Williston has higher earnings, but lower revenue than Innovus Pharmaceuticals.

Summary

Innovus Pharmaceuticals beats Williston on 4 of the 7 factors compared between the two stocks.


Innovus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.20+2.4%$11.16 millionN/A0.00
TOWTF
Tower One Wireless
0.0$0.12+0.5%$11.06 million$4.08 million-1.33
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.12+3.9%$10.94 million$7.38 million0.00High Trading Volume
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.14+0.3%$10.59 millionN/A0.00
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.40+19.3%$9.60 millionN/A0.00
WHCA
Williston
0.0$0.70+64.3%$9.51 millionN/A0.00Gap Down
ULUR
ULURU
0.3$0.28+0.0%$8.17 millionN/A0.00
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.34+0.0%$7.52 million$2.66 million-11.33Gap Up
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36+0.0%$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08+48.8%$7.15 millionN/A0.00Gap Down
KAYS
Kaya
0.7$0.44+1.1%$6.89 million$1.01 million0.00Gap Down
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.24+12.5%$5.57 million$3.48 million-1.96Gap Down
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.73+0.0%$5.50 million$9.47 million0.00Gap Up
BCTXF
BriaCell Therapeutics
0.0$5.95+1.3%$4.59 millionN/A-0.01
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.04+30.6%$4.56 million$30,000.000.00Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11+4.2%$4.38 million$3.65 million0.00
AMBS
Amarantus BioScience
0.0$0.01+16.8%$4.37 millionN/A0.00Gap Down
FutureWorld logo
FWDG
FutureWorld
0.5$0.00+0.0%$3.80 millionN/A0.00Gap Up
AKRXQ
Akorn
0.1$0.03+0.7%$3.60 million$682.43 million-0.01
VGLS
VG Life Sciences
0.0$0.01+2.7%$3.50 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.03+3.7%$3.00 million$20,000.00-1.35Gap Up
RSPI
RespireRx Pharmaceuticals
0.5$0.04+8.5%$2.76 millionN/A-0.08
NSPX
Inspyr Therapeutics
0.5$0.01+2.0%$2.21 millionN/A0.00
VVUSQ
VIVUS
0.6$0.12+1.5%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.31+11.3%$2.10 millionN/A0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$34.00+5.9%$1.84 million$2 million0.00Gap Down
WWHC
W World
0.8$6.09+4.8%$1.80 millionN/A0.00High Trading Volume
Gap Up
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.50+25.8%$1.76 millionN/A0.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.10+4.8%$1.67 million$710,000.000.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03+7.0%$1.54 million$530,000.000.00Gap Down
MLNTQ
Melinta Therapeutics
0.2$0.11+7.9%$1.51 million$96.43 million0.00Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.02+12.2%$1.30 million$8.73 million0.00
AOLS
Aeolus Pharmaceuticals
0.8$0.01+15.4%$1.19 millionN/A0.00Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05+388.2%$1.12 millionN/A-0.57Upcoming Earnings
High Trading Volume
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.24+4.8%$1.12 millionN/A0.00
ATRX
Adhera Therapeutics
0.0$0.09+17.6%$1.11 million$250,000.000.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04+14.9%$1.08 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01+1.4%$1.05 millionN/A0.00
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.05+16.9%$1.03 millionN/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.03+8.8%$1.01 millionN/A0.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+11.0%$996,000.00N/A0.00Gap Down
PXYN
Praxsyn
0.6$0.00+25.0%$848,000.00N/A0.00Gap Up
STLT
Spotlight Innovation
0.5$0.02+55.6%$772,000.00N/A0.00Gap Down
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03+29.2%$771,000.00N/A0.00
SKVI
Skinvisible
0.7$0.15+0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05+16.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$5.98+51.8%$454,000.00N/A0.00Gap Up
BSPM
Biostar Pharmaceuticals
0.0$0.17+12.1%$436,000.00N/A0.00Gap Up
HSTC
HST Global
0.8$0.07+108.3%$378,000.00N/A0.00High Trading Volume
Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02+25.3%$366,000.00N/A0.00Gap Down
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.